close

N-Glycan Analysis: The Cornerstone of Biologic Quality Control

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

N-Glycan analysis is a critical quality attribute (CQA) for antibody drugs, directly impacting stability, efficacy, ADCC/CDC activity, half-life, and immunogenicity risk control.

Hyasen Biotech N-Glycan Analysis Kits

Hyasen Biotech provides a complete, ready-to-use N-Glycan analysis solution designed to simplify and accelerate your biologic QC workflow:

  • Ultra-fast workflow: Entire process completed in
  • High-efficiency PNGase F digestion: 5-minute rapid digestion with 100% digestion efficiency for IgG1, IgG4, fusion proteins, and other glycoproteins.
  • Outstanding analytical performance: Excellent repeatability, linearity (R² > 0.99), and batch-to-batch consistency with CV < 10% for key glycoforms.
  • Regulatory & benchmark alignment: Glycan profiles and retention times highly consistent with top imported kits, fully compliant with pharmacopoeia requirements for filing and release.

Empower Your Biologics Development

Backed by robust method validation and real-world customer applications, Hyasen N-Glycan Analysis Kits deliver reliable, sensitive, and time-saving performance for biopharmaceutical R&D and quality control. Partner with Hyasen to enhance efficiency, ensure compliance, and accelerate the development and commercialization of your biologics.

图片1(3) (1).png

Media Contact
Company Name: Hyasen Biotech
Email: Send Email
Country: China
Website: https://www.hyasen.com/

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  265.29
-1.03 (-0.39%)
AAPL  308.33
-0.49 (-0.16%)
AMD  503.89
+36.38 (7.78%)
BAC  52.20
+0.40 (0.77%)
GOOG  384.84
+5.46 (1.44%)
META  612.34
+2.08 (0.34%)
MSFT  416.03
-2.54 (-0.61%)
NVDA  214.86
-0.47 (-0.22%)
ORCL  193.06
+0.98 (0.51%)
TSLA  433.59
+7.58 (1.78%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today